Review Reports
- Rocco Latorre 1,2,
- Maria Chiara Valerii 3 and
- Paolo Gaibani 4,7,*
- et al.
Reviewer 1: Anonymous Reviewer 2: Anonymous Reviewer 3: Shivaji B. Markad Reviewer 4: Taras Pyatkovskyy
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThis study evaluates the in vitro synergistic potential of three essential oil (EO) components—eugenol, cinnamaldehyde, and carvacrol—in combination with conventional antibiotics against multidrug-resistant Gram negative bacteria. The authors utilize whole genome sequencing to characterize the resistance determinants of seven clinical isolates and employ checkerboard assays to determine the FICI.
The study provides an interesting phenotypic observation of synergy between these essential oil components and colistin. However, until the authors provide mechanistic data or cytotoxicity profiles to support the clinical relevance of these high-concentration combinations, the manuscript is not yet suitable for publication.
Major Issues
- Sample size: The study relies on only seven clinical isolates. This is a critically small sample size for a study claiming "high synergistic activity" against broad categories like carbapenem-producing Enterobacterales (CPE) and Carbapenem-Resistant Acinetobacter baumannii (CRAB).. The authors should expand the panel to include a more diverse array of sequence types and resistance profiles to ensure the findings are not strain-specific. Additionally, while E coli BL21 is used as a control, the authors should include standard ATCC reference strains for K. pneumoniae and A. baumanni to establish baseline susceptibility.
- High MICs and Toxicity Concerns: The baseline MICs for the EO components are extremely high, ranging from 512 to 2,048 mg/l. Even with a 4 fold reduction in MIC due to synergy, the resulting concentrations (eg.., 256 to 512 mg/l) remain significantly above clinically achievable serum levels for most antimicrobials. Authors suggest these combinations could "mitigate toxicity to eukaryotic cells" by reducing colistin dosages. However, the study lacks any cytotoxicity data, such as MTT assays on cell lines, to prove that these high concentrations of EO components are themselves non-toxic
- Regarding the genomic analysis, isolate Kp51 (ST16) harbors bla_{OXA-181} but lacks a primary carbapenemase like KPC or NDM found in other isolates. Did the authors observe a different synergistic response in this specific isolate compared to the KPC/NDM-producing strains?
- The study utilized a 5% DMSO concentration for resuspension, noting it had a "modest effect" on growth. Did the authors perform a checkerboard assay using a "no-DMSO" control to confirm that the solvent itself did not contribute to membrane sensitization, particularly in the colistin combinations?
- The FICI interpretation for carvacrol + colistin showed synergy in 50% of strains. However, the reported mean FICI was 0.5743 (line 367), which technically falls into the "indifferent" or additive range according to the authors' own defined criteria. Can the authors clarify the statistical significance of the "synergy" label for these specific interactions?
Minor Issues
1. Line 288: Does the average (mean) value for cinnamaldehyde include the control bacteria, or does it only count the drug-resistant samples? Please clarify exactly which group of bacteria this number represents so the results are easy to verify.
2. Line 28: "inclining" should be replaced with "including"
3. In many places written “,” instead of “.” (E.g. line 367: 0,5743 should be replaced with 0.5743)
Author Response
Comments and Suggestions for Authors
This study evaluates the in vitro synergistic potential of three essential oil (EO) components—eugenol, cinnamaldehyde, and carvacrol—in combination with conventional antibiotics against multidrug-resistant Gram negative bacteria. The authors utilize whole genome sequencing to characterize the resistance determinants of seven clinical isolates and employ checkerboard assays to determine the FICI.
The study provides an interesting phenotypic observation of synergy between these essential oil components and colistin. However, until the authors provide mechanistic data or cytotoxicity profiles to support the clinical relevance of these high-concentration combinations, the manuscript is not yet suitable for publication.
Major Issues
-
Sample size: The study relies on only seven clinical isolates. This is a critically small sample size for a study claiming "high synergistic activity" against broad categories like carbapenem-producing Enterobacterales (CPE) and Carbapenem-Resistant Acinetobacter baumannii (CRAB).. The authors should expand the panel to include a more diverse array of sequence types and resistance profiles to ensure the findings are not strain-specific. Additionally, while E coli BL21 is used as a control, the authors should include standard ATCC reference strains for K. pneumoniae and A. baumanni to establish baseline susceptibility.
Authors’ reply and amendments: We thank the Reviewer for his comments and for the time he spent reviewing the study. We agree with the reviewer’s comment that the small number of samples does not reflect the application of this combination in a clinical setting. Therefore, we modified the sentence in the abstract, and we added a sentence describing this limit in the discussion section to better clarify the limits for the readers. At the same time, our study provides the synergistic activity of this combination against clinical strains representative of the major pathogen types defined by the WHO
-
High MICs and Toxicity Concerns: The baseline MICs for the EO components are extremely high, ranging from 512 to 2,048 mg/l. Even with a 4 fold reduction in MIC due to synergy, the resulting concentrations (eg.., 256 to 512 mg/l) remain significantly above clinically achievable serum levels for most antimicrobials. Authors suggest these combinations could "mitigate toxicity to eukaryotic cells" by reducing colistin dosages. However, the study lacks any cytotoxicity data, such as MTT assays on cell lines, to prove that these high concentrations of EO components are themselves non-toxic
Authors’ reply and amendments: We thank the reviewer for his comments and suggestions to improve the quality of the manuscript. We agree that the concentration of these combinations is so high that it cannot be translated at this moment to their clinical usage. To respond to this question, we are planning to perform further study regarding the in vitro and in vivo toxicity of these combinations; however, in agreement with the reviewer’s comment, we suppose that the data presented could be used as an indication for further confirmation experiments, as indicated by the reviewer. Therefore, we describe this limit in the discussion section to better clarify this point
-
Regarding the genomic analysis, isolate Kp51 (ST16) harbors bla_{OXA-181} but lacks a primary carbapenemase like KPC or NDM found in other isolates. Did the authors observe a different synergistic response in this specific isolate compared to the KPC/NDM-producing strains?
Authors’ reply and amendments: We thank the reviewer for this important comment. Clinical strains included in this study were selected as representatives of Class A (KPC), Class B (NDM), and Class D (OXA-181)carbapenemase. Thus, we opted to include the Kp51 strain as a representative strain for Class D carbapenemase producers. To respond to the important question raised by the reviewer, based on our results, we did not observe a significant difference against the Kp51 strain.
-
The study utilized a 5% DMSO concentration for resuspension, noting it had a "modest effect" on growth. Did the authors perform a checkerboard assay using a "no-DMSO" control to confirm that the solvent itself did not contribute to membrane sensitization, particularly in the colistin combinations?
Authors’ reply and amendments: We thank the reviewer for his comment. Our experiments performed without no-DMSO control confirmed our results.
-
The FICI interpretation for carvacrol + colistin showed synergy in 50% of strains. However, the reported mean FICI was 0.5743 (line 367), which technically falls into the "indifferent" or additive range according to the authors' own defined criteria. Can the authors clarify the statistical significance of the "synergy" label for these specific interactions?
Authors’ reply and amendments: We thank the reviewer for his important question. The FIC value was calculated against every single isolate and combination, and the synergistic activity was considered only for a FIC value lower than 0.5. The results were described both in terms of the FIC for every single isolate and for the aggregate data. In this context, the statistical difference was observed for the mean and not every single value, following appropriate statistical analysis. Thus, a brief sentence was added to the results to better clarify this point
Minor Issues
1. Line 288: Does the average (mean) value for cinnamaldehyde include the control bacteria, or does it only count the drug-resistant samples? Please clarify exactly which group of bacteria this number represents so the results are easy to verify.
Authors’ reply and amendments: The strains tested was added to the text as requested
2. Line 28: "inclining" should be replaced with "including"
Authors’ reply and amendments: The term was modified as indicated
3. In many places written “,” instead of “.” (E.g. line 367: 0,5743 should be replaced with 0.5743)
Authors’ reply and amendments: The number was modified accordingly to the reviewer’sd indication
Reviewer 2 Report
Comments and Suggestions for AuthorsThe central idea of the article is relevant and addresses a well-defined clinical issue, but the writing lacks effectiveness. The structure is repetitive, the review of the literature is poorly organized, and key information is scattered, which detracts from the clarity and impact of the argument. A concise and better-organized rewrite would better highlight the quality of the results obtained. Here below are some comments to enhance the article for an eventual reconsideration:
Abstract
Line 36, “Our data demonstrated showed that” is a redundant double verb; it should be “Our data demonstrated that” or “Our results showed that.”
Line 27, “inclining” seems to be a typographical error; it is likely meant to be “including.”
The synergy percentages (37.5–50%) are given without specifying whether they correspond to the proportion of isolates exhibiting synergy or to the reduction in MIC values; the wording needs to be clarified.
line 32, the range *“87.5–100 %”* associated with β-lactams and gentamicin is ambiguous; it would be clearer to explicitly state that no synergy was observed for 87.5 to 100% of the isolates.
the conclusion repeats a similar idea twice (“our data demonstrated showed” and then “our results suggest”); a single statement is sufficient.
Introduction
line 62, “limited effective therapeutic options” is slightly redundant; “limited therapeutic options” suffices.
line 79, “(3)” instead of “[3]” for the reference citation; inconsistency in citation formatting (some in square brackets, others not).
line 70, “contribute to generate a favorable environment” is a syntactic anglicism; prefer “contribute to creating a favorable environment”.
line 80, “Enterobacterales, including Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae complex, Citrobacter spp., and Serratia marcescens” → the grammatical structure could be improved to avoid an overly long and disjointed sentence.
Some sentences are very long (e.g., lines 68–71), which detracts from clarity; breaking them into shorter sentences would improve readability.
In line 84, the phrase “historically used as a last line of defense” could be moved earlier in the sentence to avoid an information overload at the end of the paragraph.
line 138, “colistin or gentamicin” should be preceded by a comma in the list (“ceftazidime, cefepime, meropenem, colistin or gentamicin”) for clarity.
line 108, “underscore a critical need for novel antimicrobial approaches”; the term “critical” is used frequently throughout the text (e.g., lines 61, 63, 107), creating redundancy.
lines 116–117, *“compared to single-target antibiotics [10]”*; reference [10] has already been cited several times, but the line break between sentences could be better managed to avoid a visual disruption.
line 138, “across panels of well-characterized clinical isolates” → the phrasing is correct but could be simplified to “using panels”; alternatively, “across panels of well-characterized clinical isolates” remains acceptable.
line 132, “Despite these promising observations” is a good transition, but the following paragraph would benefit from more explicitly introducing the objective of the study presented in the article.
line 140, “MDR Gram-negative (GNB) infections” → the abbreviation GNB is not defined in this section; it appears earlier in the text (lines 26 and 48–49), but a redefinition would be helpful for the flow of the text.
line 140, “can serve” (present tense) whereas the rest of the text mainly uses the simple present; this remains consistent but should be checked against the rest of the manuscript.
Discussion
Lines 382–384, “even if sporadic synergistic interactions were observed. Indeed, although we observed sporadic synergistic effects of these combinations,” present a double repetition of the same concept. A single mention is sufficient.
line 380, “including ESBL and carbapenemase-producing strains” repeats information already provided in lines 376–377. The characterization of the strains should be presented only once.
line 379, “both eugenol, cinnamaldehyde, and carvacrol” is incorrect. “Both” is used for two elements; for three, one should use “eugenol, cinnamaldehyde, and carvacrol” or “all three compounds.”
lines 384–388, the sentence regarding the absence of clinically relevant synergy is too long and repeats the idea several times (“unlikely to be clinically effective,” “insufficient to reduce MICs to clinically treatable levels”). A more concise formulation would be preferable.
line 390, “Our findings are consistent with those of previous investigations” is a standard transition, but the following paragraph mixes mechanistic explanation with discussion of the results, which detracts from the clarity of the structure.
Author Response
Comments and Suggestions for Authors
The central idea of the article is relevant and addresses a well-defined clinical issue, but the writing lacks effectiveness. The structure is repetitive, the review of the literature is poorly organized, and key information is scattered, which detracts from the clarity and impact of the argument. A concise and better-organized rewrite would better highlight the quality of the results obtained. Here below are some comments to enhance the article for an eventual reconsideration:
Abstract
Line 36, “Our data demonstrated showed that” is a redundant double verb; it should be “Our data demonstrated that” or “Our results showed that.”
Authors’ reply and amendments: We thank the Reviewer for his comments and for the time he spent reviewing the study. We modified the sentence according to the reviewer’s comment.
Line 27, “inclining” seems to be a typographical error; it is likely meant to be “including.”
Authors’ reply and amendments: We modified the sentence accordingly to the reviewer’s comment.
The synergy percentages (37.5–50%) are given without specifying whether they correspond to the proportion of isolates exhibiting synergy or to the reduction in MIC values; the wording needs to be clarified.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
line 32, the range *“87.5–100 %”* associated with β-lactams and gentamicin is ambiguous; it would be clearer to explicitly state that no synergy was observed for 87.5 to 100% of the isolates.
the conclusion repeats a similar idea twice (“our data demonstrated showed” and then “our results suggest”); a single statement is sufficient.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
Introduction
line 62, “limited effective therapeutic options” is slightly redundant; “limited therapeutic options” suffices.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
line 79, “(3)” instead of “[3]” for the reference citation; inconsistency in citation formatting (some in square brackets, others not).
Authors’ reply and amendments: The reference was modified accordingly to the reviewer’s comment.
line 70, “contribute to generate a favorable environment” is a syntactic anglicism; prefer “contribute to creating a favorable environment”.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
line 80, “Enterobacterales, including Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae complex, Citrobacter spp., and Serratia marcescens” → the grammatical structure could be improved to avoid an overly long and disjointed sentence.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
Some sentences are very long (e.g., lines 68–71), which detracts from clarity; breaking them into shorter sentences would improve readability.
Authors’ reply and amendments: The sentence was completely modified accordingly to the reviewer’s comment.
In line 84, the phrase “historically used as a last line of defense” could be moved earlier in the sentence to avoid an information overload at the end of the paragraph.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
line 138, “colistin or gentamicin” should be preceded by a comma in the list (“ceftazidime, cefepime, meropenem, colistin or gentamicin”) for clarity.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
line 108, “underscore a critical need for novel antimicrobial approaches”; the term “critical” is used frequently throughout the text (e.g., lines 61, 63, 107), creating redundancy.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
lines 116–117, *“compared to single-target antibiotics [10]”*; reference [10] has already been cited several times, but the line break between sentences could be better managed to avoid a visual disruption.
Authors’ reply and amendments: The reference was modified accordingly to the reviewer’s comment.
line 138, “across panels of well-characterized clinical isolates” → the phrasing is correct but could be simplified to “using panels”; alternatively, “across panels of well-characterized clinical isolates” remains acceptable.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
line 132, “Despite these promising observations” is a good transition, but the following paragraph would benefit from more explicitly introducing the objective of the study presented in the article.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
line 140, “MDR Gram-negative (GNB) infections” → the abbreviation GNB is not defined in this section; it appears earlier in the text (lines 26 and 48–49), but a redefinition would be helpful for the flow of the text.
Authors’ reply and amendments: The abbreviation was modified accordingly to the reviewer’s comment.
line 140, “can serve” (present tense) whereas the rest of the text mainly uses the simple present; this remains consistent but should be checked against the rest of the manuscript.
Authors’ reply and amendments: The verb was modified accordingly to the reviewer’s comment and the text was entirely checked
Discussion
Lines 382–384, “even if sporadic synergistic interactions were observed. Indeed, although we observed sporadic synergistic effects of these combinations,” present a double repetition of the same concept. A single mention is sufficient.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
line 380, “including ESBL and carbapenemase-producing strains” repeats information already provided in lines 376–377. The characterization of the strains should be presented only once.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
line 379, “both eugenol, cinnamaldehyde, and carvacrol” is incorrect. “Both” is used for two elements; for three, one should use “eugenol, cinnamaldehyde, and carvacrol” or “all three compounds.”
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
lines 384–388, the sentence regarding the absence of clinically relevant synergy is too long and repeats the idea several times (“unlikely to be clinically effective,” “insufficient to reduce MICs to clinically treatable levels”). A more concise formulation would be preferable.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
line 390, “Our findings are consistent with those of previous investigations” is a standard transition, but the following paragraph mixes mechanistic explanation with discussion of the results, which detracts from the clarity of the structure.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
Reviewer 3 Report
Comments and Suggestions for AuthorsIn the article “Synergistic activity of eugenol, cinnamaldehyde and carvacrol in combination with different antimicrobial molecules against Multi Drug-Resistant Gram-Negative clinical isolates” author evaluated synergistic interaction was not affected by different antimicrobial resistance genes and/or different antimicrobial susceptibility profiles.
The synergistic interactions between carvacrol, eugenol, and cinnamaldehyde with colistin represent a promising strategy to counteract MDR-GNB bacteria. It reduces the dosage of these molecules and colistin, potentially mitigating their toxicity to eukaryotic cells.
The articles are suitable for publication based on their importance content and future application of cytotoxic effect in combinations.
Following corrections were recommended before publications:
The figures are small size, it’s only half page, so it does not look very clear. I would like to increase the size of all figures so it will fit to complete page horizontally.
In reference section: The reference 7, included two references year, volume and page number. Use separate numbers or semi comma in between references.
Page numbers, volume, and years were not following journal guidelines. Check all other references and correct all the references by using journal guidelines.
Author Response
Comments and Suggestions for Authors
In the article “Synergistic activity of eugenol, cinnamaldehyde and carvacrol in combination with different antimicrobial molecules against Multi Drug-Resistant Gram-Negative clinical isolates” author evaluated synergistic interaction was not affected by different antimicrobial resistance genes and/or different antimicrobial susceptibility profiles.
The synergistic interactions between carvacrol, eugenol, and cinnamaldehyde with colistin represent a promising strategy to counteract MDR-GNB bacteria. It reduces the dosage of these molecules and colistin, potentially mitigating their toxicity to eukaryotic cells.
The articles are suitable for publication based on their importance content and future application of cytotoxic effect in combinations.
Following corrections were recommended before publications:
The figures are small size, it’s only half page, so it does not look very clear. I would like to increase the size of all figures so it will fit to complete page horizontally.
Authors’ reply and amendments: We thank the Reviewer for his comments and for the time he spent reviewing the study. We enlarge the figure’s sizes to improve the quality as requested
In reference section: The reference 7, included two references year, volume and page number. Use separate numbers or semi comma in between references.
Authors’ reply and amendments: The reference was modified as suggested
Page numbers, volume, and years were not following journal guidelines. Check all other references and correct all the references by using journal guidelines.
Authors’ reply and amendments: The references were revised accordingly to the journal style
Reviewer 4 Report
Comments and Suggestions for AuthorsThe manuscript is interesting but requires a revision, comments below.
Title
The authors use the term "antimicrobial molecules". In the Materials and Methods section, they list them as cefepime, ceftazidime, meropenem, colistin, and gentamicin. Why not use "antibiotics", "antibacterials", or "antibacterial agents"?
Abstract
Lines 36-37. "Our data demonstrated showed that..." No need for two verbs.
Introduction
No comments
Materials and Methods
2.1. Phenotypic analysis should be divided into two subchapters: 2.1. clinical strains isolation and identification. 2.2. Antibiotic susceptibility testing.
Lines 151-152: "Clinical strains included in this study were isolated from patients recovered in a large teaching hospital located in northern part of Italy". The sentence needs clarification. What patients? How many? What diagnoses and what samples were collected to isolate microorganisms? Specify the hospital.
Please also clarify if ethical approval was obtained for the use of clinical isolates.
Line 152 and line 162: no information is provided regarding the isolation and culturing of strains. What culture media were used to inoculate the samples?
2.3. Cinnamaldehyde, eugenol, carvacrol, and antibiotics powders preparation
Line 196: There is a typo - "105 CFU/ml" The exponentiation is not denoted properly.
2.4. MIC evaluation should be moved to Antibiotic susceptibility testing.
Line 202: same as in the title - "antimicrobial molecules" are "antibiotics"
Line 203: "BL21 competent E. coli" - more information about the strain is required. What is the source of that strain, and why was it chosen as a control?
Results
The section about the strains is missing. How many strains from how many patients were isolated? Why only GN were selected for the study? Why were GP strains omitted? Why, among GN strains, did the authors pick only Klebsiella, Acinetobacter, and E. coli? Were there other GN strains?
Discussion
Line 416: The number of strains was never mentioned and may be assumed from Table 1 only.
Conclusion
There is no conclusion section, just the conclusion paragraph.
Line 423: There shouldn't be any references in the conclusion section/paragraph.
Author Response
Comments and Suggestions for Authors
The manuscript is interesting but requires a revision, comments below.
Title
The authors use the term "antimicrobial molecules". In the Materials and Methods section, they list them as cefepime, ceftazidime, meropenem, colistin, and gentamicin. Why not use "antibiotics", "antibacterials", or "antibacterial agents"?
Authors’ reply and amendments: We thank the Reviewer for his comments and for the time he spent reviewing the study. The title was modified accordingly to the reviewer’s comment.
Abstract
Lines 36-37. "Our data demonstrated showed that..." No need for two verbs.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
Introduction
No comments
Materials and Methods
2.1. Phenotypic analysis should be divided into two subchapters: 2.1. clinical strains isolation and identification. 2.2. Antibiotic susceptibility testing.
Authors’ reply and amendments: We thank the Reviewer for his comments and for the time he spent reviewing the study. We opted to maintain the Material and Methods section in this format for clarity of methods description
Lines 151-152: "Clinical strains included in this study were isolated from patients recovered in a large teaching hospital located in northern part of Italy". The sentence needs clarification. What patients? How many? What diagnoses and what samples were collected to isolate microorganisms? Specify the hospital. also clarify if ethical approval was obtained for the use of clinical isolates.
Authors’ reply and amendments: We thank the Reviewer for his comments and for the time he spent reviewing the study. The strains were collected and described in other studies, and in this study, they were used anonymously for the experiments. The strains were selected as representative of the different carbapenemase types (A, B, and D), ESBL, and no AMR genes. Indeed, the aim of this study is not to correlate with clinical data that are not available for these strains and do not require ethical approval, but to provide evidence of the essential oils/ antimicrobial interaction against representative strains. Further studies will be performed to respond to the important question raised by the reviewer and to correlate the synergy data with clinical outcomes
Line 152 and line 162: no information is provided regarding the isolation and culturing of strains. What culture media were used to inoculate the samples?
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
2.3. Cinnamaldehyde, eugenol, carvacrol, and antibiotics powders preparation
Line 196: There is a typo - "105 CFU/ml" The exponentiation is not denoted properly.
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
2.4. MIC evaluation should be moved to Antibiotic susceptibility testing.
Authors’ reply and amendments: We thank the Reviewer for his comments and for the time he spent reviewing the study. We opted to maintain this section after the DMSO paragraph for clarity of the method used in this study
Line 202: same as in the title - "antimicrobial molecules" are "antibiotics"
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
Line 203: "BL21 competent E. coli" - more information about the strain is required. What is the source of that strain, and why was it chosen as a control?
Authors’ reply and amendments: The sentence was modified accordingly to the reviewer’s comment.
Results
The section about the strains is missing. How many strains from how many patients were isolated? Why only GN were selected for the study? Why were GP strains omitted? Why, among GN strains, did the authors pick only Klebsiella, Acinetobacter, and E. coli? Were there other GN strains?
Authors’ reply and amendments: As discussed in the previous point, the strains derived from other epidemiological studies were selected on the basis of the phenotype/genotype as representative clinical bacteria carrying class A, B, and D carbapenemase, ESBL, and no AMR genes. Also, Gram-positive bacteria are not in the focus of the study because the strains selected were chosen among the priority pathogens with MDR phenotype as indicated by WHO. However, considering the important suggestion provided by the reviewer, other GN strains will be evaluated in further studies to evaluate the activity of these combinations against a large number of isolates and species
Discussion
Line 416: The number of strains was never mentioned and may be assumed from Table 1 only.
Authors’ reply and amendments: We modified the sentence in the discussion section to better clarify that the strains included in this study were selected as representative fo MDR pathogens listed by WHO
Conclusion
There is no conclusion section, just the conclusion paragraph.
Authors’ reply and amendments: A conclusion section was added accordingly to the reviewer’s comment.
Line 423: There shouldn't be any references in the conclusion section/paragraph.
Authors’ reply and amendments: A reference was added to the conclusion section as requested
Round 2
Reviewer 1 Report
Comments and Suggestions for AuthorsThe study provides an interesting observation of synergy with colistin, but a Major Revision is required to address several scientific gaps:
- Sample size: Testing only seven isolates is insufficient to generalize synergy across broad MDR-GNB categories.
- Toxicity: MICs remain extremely high (256–512~mg/l), requiring cytotoxicity data (e.g. MTT assays) to ensure these combinations are safe for human cells.
- Statistical logic: The mean FICI for carvacrol + colistin (0.5743) exceeds your own < 0.5 threshold for synergy
Author Response
The study provides an interesting observation of synergy with colistin, but a Major Revision is required to address several scientific gaps:
-
Sample size: Testing only seven isolates is insufficient to generalize synergy across broad MDR-GNB categories.
Authors’ reply and amendments: We agree with the reviewer that a panel of seven clinical isolates limits the generalizability of our conclusions. Our study was designed as a proof‑of‑concept investigation to evaluate whether plant‑derived compounds (AKA essential oils) could enhance colistin activity against representative multidrug‑resistant Gram‑negative bacteria (MDR‑GNB), rather than to provide population‑level epidemiological conclusions. To avoid over-interpretation, we have revised the manuscript as follows: We now state in the Discussion that the limited number of isolates represents a key limitation of the study.
Clarify that the observed synergy should be interpreted as strain‑specific and exploratory, not universally applicable to all multidrug‑resistant Gram‑negative bacteria.
-
Toxicity: MICs remain extremely high (256–512~mg/l), requiring cytotoxicity data (e.g. MTT assays) to ensure these combinations are safe for human cells.
Authors’ reply and amendments: We agree that the absolute MIC values of the phytochemicals are high and that toxicity considerations are essential for translational relevance. Importantly, the goal of this study was not to propose direct systemic application of these compounds at MIC‑equivalent concentrations, but rather to investigate their adjuvant potential in restoring colistin activity at substantially lower concentrations. We are applying to European and American funds to expand and complete our study, adding cytotoxicity experiments and in vivo efficacy and tolerability of the synergistic combinations.
-
Statistical logic: The mean FICI for carvacrol + colistin (0.5743) exceeds your own < 0.5 threshold for synergy
Authors’ reply and amendments: We agree that the FICI value of 0.543 is higher than the synergy threshold; however, the FIC value was calculated against every single isolate and combination, and the percentage of synergy (i.e., FIC < 0.5) was expressed as a percentage among the selected isolates included in the study. At the same time, the statistical difference was observed for the mean and not every single value, following appropriate statistical analysis.
Reviewer 2 Report
Comments and Suggestions for AuthorsNo comments
Comments on the Quality of English LanguageNo comments
Author Response
Authors’ reply and amendments: We thank the Reviewer for his comments and for the time he spent reviewing the study.
Reviewer 4 Report
Comments and Suggestions for AuthorsThe quality of the manuscript has been improved. Still some parts need to be polished.
Major comment.
The MIC determination is still separated. It is in "Phenotypic analysis" (lines 161-170) and "MIC evaluation" (lines 204-215). The current structure makes the methodology difficult to follow.
Minor comments.
The authors neglected three comments from the previous review.
Please add justification for the use of BL21 competent E. coli as a control.
Previously line 202, now line 205: replace "antimicrobial molecules" with "antibiotics" or "antimicrobials".
Conclusion
Previously line 423, now line 432: There shouldn't be any references in the conclusion section. It is labelled yellow but still there.
Author Response
The quality of the manuscript has been improved. Still some parts need to be polished.
Major comment.
The MIC determination is still separated. It is in "Phenotypic analysis" (lines 161-170) and "MIC evaluation" (lines 204-215). The current structure makes the methodology difficult to follow.
Authors’ reply and amendments: We thank the Reviewer for his comments and for the time he spent reviewing the study.We moved the “MIC evaluation” section within the “Phenotypic analysis” section as requested
Minor comments.
The authors neglected three comments from the previous review.
Please add justification for the use of BL21 competent E. coli as a control.
Authors’ reply and amendments: We added to the Material and Methods section a description of the rationale to use this strain as control, as requested
Previously line 202, now line 205: replace "antimicrobial molecules" with "antibiotics" or "antimicrobials".
Authors’ reply and amendments: The term was modified, as requested
Conclusion
Previously line 423, now line 432: There shouldn't be any references in the conclusion section. It is labelled yellow but still there.
Authors’ reply and amendments: References were added to the indicated sentence, as requested
Round 3
Reviewer 1 Report
Comments and Suggestions for AuthorsThe study is now framed as an exploratory "proof-of-concept" investigation. A limitations section acknowledges the seven-isolate sample size is small. Further, future research is planned to include essential safety and cytotoxicity testing. Statistical data and language errors were corrected to meet professional standard, so it acceptable for publication.
Author Response
Authors’ reply and amendments: We thank the Reviewer for his comments and for the time he spent reviewing the study.
Reviewer 4 Report
Comments and Suggestions for AuthorsMinor comment: There still is a reference in the conclusion section, previously 33, now 34. Please move it to the discussion section or remove it entirely.
Author Response
Authors’ reply and amendments: the reference in the conclusion section was removed, as requested